Stay Connected
Join us on Facebook Follow us on linked in Follow us on YouTube Follow us on Vimeo
cardiovascular CRO experts, experience and execution
Cardiovascular Clinical Research
request info
First Name*:
Last Name*:
Leave a Message:

Please enter the security code

Find out how our medical, regulatory, and operational expertise in cardiovascular clinical development can help with your next study or program.

Learn more


Medpace is a full and active member of the Cardiac Safety Reserach Consortium. The Cardiac Safety Research Consortium (CSRC) was launched in 2006 through a MOU with Duke University to support research into the evaluation of cardiac safety of medical products. CSRC supports research by engaging stakeholders from industry, academia, and government to share data and expertise. Outputs of the CSRC include research projects taking advantage of waveforms released from the FDA ECG warehouse, “Think Tank Incubator” programs, and consensus white papers.

Medpace is home to renowned regulatory and therapeutic experts who are committed to the complex and intertwined areas of cardiovascular clinical research.

With extensive experience in Phase I-IV research, our team of international therapeutic leaders have dedicated their careers to bringing drugs to market that treat or prevent heart disease. In fact, they have helped pioneer many of the preventative cardiovascular compounds introduced in the last 15 years.

Medpace regulatory experts are former government officials who have invaluable insight into the specific area of cardiovascular drug and medical device approval. They are an integral part of every study and their valuable guidance ensures every step efficiently accelerates the approval process.

Medpace experience in large cardiovascular endpoint trials

The Medpace ability to integrate cardiovascular trials with metabolic/endocrinology projects across both therapeutic and regulatory knowledge bases provides sponsors with unique capabilities for large studies demanding rigorous safety requirements. Electronic endpoint adjudication capabilities coupled with strategic consultation and management of all outcomes and regulatory requirements, keeps projects on track.

Therapeutic Categories

  • Acute coronary syndrome
  • Coronary artery disease
  • Hypertension
  • Stroke
  • Heart failure
  • Atherosclerosis
  • STEMI and non-STEMI

Cardiovascular Site Identification and Feasibility:

Cardiovascular research often calls for high study enrolment which may lead to competition for investigators and patients. Medpace is unique in the industry in terms of its many long-term relationships with key Investigators and opinion leaders worldwide that specialize in cardiovascular trials. The Investigators, many of whom are renowned scientists and opinion leaders in the field, are well-known to the Medpace Medical Monitors and operations staff since they have worked with us for many years. These relationships facilitate more accurate assessments of whether the objectives of a study can be met within the proposed timelines. The rationale for the study design and, importantly, the proposed eligibility criteria are discussed directly with Investigators. This leads to greater involvement of the Investigators in the conduct of the study, which translates to better recruitment and study management.

Cardiac Safety - ECG Core Lab - Thorough QT Studies:

In addition to full-service CRO functionality, Medpace’s capabilities include core laboratory services in ECG technologies. The Medpace ECG Core Laboratory provides sponsors with reliable, consistent, and prompt electrocardiographic services in support of global clinical development programs to support international Phase I–IV clinical trials. With the intense focus on cardiac safety from regulatory authorities, Medpace also has the integrated services and experts to manage the rigors of TQT studies.

Medical Device:

Medpace Medical Device (MMD) is a wholly-owned division of Medpace exclusively dedicated to the design and conduct of medical device trials. MMD has vast experience in cardiovascular trials including:
  • Coronary, Peripheral and Carotid Stents
  • Aortic Valve Replacement
  • RF Ablation for A-fib
  • Endovascular interventions
  • ICD/CRT-D and Pacemakers
  • LVAD